As pharma companies require increasing revenues to keep growth rates intact, it is unclear whether they will be attracted only to large products that can have a significant impact on their own, or whether they will be willing to layer sales from smaller product opportunities.

IntraBiotics Pharmaceuticals Inc. (Mountain View, Calif.) has its answer. However, the biotech company is happy to continue pursuit of a product with reduced risk on its own even though former partner Pharmacia & Upjohn S.p.A. has decided that the market for the compound is too small.